PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
238.00 - 242.07
140.53 - 242.25
26.77M / 38.44M (Avg.)
25.64 | 9.39
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-10.67%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-11.49%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-13.91%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-13.91%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-35.94%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-35.06%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-36.36%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
-0.34%
Share reduction while META is at 0.09%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.42%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
No Data
No Data available this quarter, please select a different quarter.
-20.63%
Negative OCF growth while META is at 21.12%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-34.97%
Negative FCF growth while META is at 49.37%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
462.67%
10Y revenue/share CAGR under 50% of META's 1978.81%. Michael Burry would suspect a lasting competitive disadvantage.
136.56%
5Y revenue/share CAGR under 50% of META's 392.37%. Michael Burry would suspect a significant competitive gap or product weakness.
67.45%
3Y revenue/share CAGR at 50-75% of META's 126.42%. Martin Whitman would question if the firm lags behind competitor innovations.
310.44%
10Y OCF/share CAGR under 50% of META's 2631.90%. Michael Burry would worry about a persistent underperformance in cash creation.
71.66%
Below 50% of META's 536.45%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
20.76%
3Y OCF/share CAGR under 50% of META's 123.00%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
223.85%
Below 50% of META's 1702.47%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
92.91%
Below 50% of META's 847.18%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
26.86%
Below 50% of META's 64.30%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
392.71%
Equity/share CAGR of 392.71% while META is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
86.28%
Below 50% of META's 176.17%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
41.48%
3Y equity/share CAGR at 50-75% of META's 73.62%. Martin Whitman sees a short-term lag in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-13.67%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
-11.01%
Inventory is declining while META stands at 0.00%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-0.91%
Negative asset growth while META invests at 3.75%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
1.45%
Under 50% of META's 4.12%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.
4.90%
Debt growth far above META's 0.19%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
-5.57%
Our R&D shrinks while META invests at 3.56%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-13.86%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.